click below
click below
Normal Size Small Size show me how
Antidiabetic Pharm
Drug | MOA | Indications | SE | CI | Notes |
---|---|---|---|---|---|
Insulin Lispro: peak in 1hr, duration 3-4hrs. Regular Insulin: peak 2-3hrs; duration 5-7hrs. Semilente insulin: peak 6hrs; duration 10-12hrs. Lente insulin/NPH: peak 10hrs, duration 18hrs. Ultralente insulin: peak 12hrs, duration 24hrs. | 1. Decr bld glucose by decr hepatic gluconeogenesis, incr glycogen syn, incr glucose uptake 2. Inhibit lypolysis 3. Incr AA uptake 4. Decr serum K (incr K uptake) | T2DM | Hypoglycemia | Syn: proinsulin -> insulin + C-peptide in pancreatic B cell. Secr: glucose binds R on B-cell -> uptake and oxidized to ATP -> ATP binds K channel and inhibit K efflux -> depolarization -> incr Ca(i) -> insulin rel -> act on liver, muscle, adipose | |
Metformin | 1. inh hepatic gluconeogenesis; 2. incr periph use of glucose by adipose and skeletal m; 3. decr abs of glucose from GI | 1. non-insulin dependent T2DM; 2. polycystic ovarian syndrome | 1. GI upset; 2. lactic acidosis; 3. impaired vit B12 abs. NO HYPOGLYCEMIA | renal insufficiency | |
Rosiglitazone "-glitazones" | bind PPAR-g -> upregulation of genes that decr insulin resistance | T2DM (non-insulin dependent) | hypoglycemia, edema | Troglitazone drawn from market for liver toxicity, CI in hepatic insufficiency. | |
Sulfonylureas | 1. bind K channels on B cell -> stim insulin release; 2. prolong binding of insulin to target tissue receptors; 3. decr serum glucagon | T2DM | hypoglycemia | pregnancy (cross placenta and cause insulin depletion); use w/caution in renal and hepatic insufficiency | |
a-glucosidase inhibitors | inhibit a-glucosidase (brush border of sm int) -> decr abs of postprandial carbs | T2DM | GI upset (flatulence, diarrhea) | ||
Meglitinides "-glinides" | binds K channel -> incr release of insulin | T2DM | wt gain, hypoglycemia | ||
Dipeptidyl peptidase-4 (DPP-4) inhibitors "-gliptins" | inhibit DDP-4 -> incr GLP-1 -> incr insulin, decr glucagon secr | T2DM | nausea | ||
Glucagon-like peptide 1 (GLP-1) analog | incr insulin and decr glucagon secr | T2DM | pancreatitis, hypoglycemia |